These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33313335)

  • 21. Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy.
    Chen Y; Zheng S; Tecedor L; Davidson BL
    Mol Ther; 2018 Apr; 26(4):1118-1126. PubMed ID: 29503202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB.
    Meadows AS; Duncan FJ; Camboni M; Waligura K; Montgomery C; Zaraspe K; Naughton BJ; Bremer WG; Shilling C; Walker CM; Bolon B; Flanigan KM; McBride KL; McCarty DM; Fu H
    Hum Gene Ther Clin Dev; 2015 Dec; 26(4):228-42. PubMed ID: 26684447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery.
    Fu H; DiRosario J; Kang L; Muenzer J; McCarty DM
    J Gene Med; 2010 Jul; 12(7):624-33. PubMed ID: 20603889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector.
    Quiviger M; Arfi A; Mansard D; Delacotte L; Pastor M; Scherman D; Marie C
    Gene Ther; 2014 Dec; 21(12):1001-7. PubMed ID: 25142140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme replacement reduces neuropathology in MPS IIIA dogs.
    Crawley AC; Marshall N; Beard H; Hassiotis S; Walsh V; King B; Hucker N; Fuller M; Jolly RD; Hopwood JJ; Hemsley KM
    Neurobiol Dis; 2011 Aug; 43(2):422-34. PubMed ID: 21550404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancing the Therapeutic Potential of Sulfamidase for the Treatment of Mucopolysaccharidosis IIIA.
    Sorrentino NC; Cacace V; De Risi M; Maffia V; Strollo S; Tedesco N; Nusco E; Romagnoli N; Ventrella D; Huang Y; Liu N; Kalled SL; Choi VW; De Leonibus E; Fraldi A
    Mol Ther Methods Clin Dev; 2019 Dec; 15():333-342. PubMed ID: 31788497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder.
    Lau AA; Rozaklis T; Ibanes S; Luck AJ; Beard H; Hassiotis S; Mazouni K; Hopwood JJ; Kremer EJ; Hemsley KM
    Gene; 2012 Jan; 491(1):53-7. PubMed ID: 21963444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IgG-cleavage protein allows therapeutic AAV gene delivery in passively immunized MPS IIIA mice.
    Bobo TA; Samowitz PN; Robinson MI; Montes LI; Forsberg LJ; Feng R; Nicely NI; Fu H
    Gene Ther; 2023 Apr; 30(3-4):377-385. PubMed ID: 36253453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
    Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
    Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.
    Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ
    Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
    Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
    Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.
    Haurigot V; Marcó S; Ribera A; Garcia M; Ruzo A; Villacampa P; Ayuso E; Añor S; Andaluz A; Pineda M; García-Fructuoso G; Molas M; Maggioni L; Muñoz S; Motas S; Ruberte J; Mingozzi F; Pumarola M; Bosch F
    J Clin Invest; 2013 Aug; 123(8):3254-3271. PubMed ID: 23863627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA.
    Crawley AC; Gliddon BL; Auclair D; Brodie SL; Hirte C; King BM; Fuller M; Hemsley KM; Hopwood JJ
    Brain Res; 2006 Aug; 1104(1):1-17. PubMed ID: 16828069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variables influencing fluorimetric
    Whyte LS; Hopwood JJ; Hemsley KM; Lau AA
    Mol Genet Metab Rep; 2015 Dec; 5():60-62. PubMed ID: 28652977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA.
    Anson DS; McIntyre C; Thomas B; Koldej R; Ranieri E; Roberts A; Clements PR; Dunning K; Byers S
    Genet Vaccines Ther; 2007 Jan; 5():1. PubMed ID: 17227588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA.
    Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S
    Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice.
    Hinderer C; Katz N; Louboutin JP; Bell P; Yu H; Nayal M; Kozarsky K; O'Brien WT; Goode T; Wilson JM
    Hum Gene Ther; 2016 Nov; 27(11):906-915. PubMed ID: 27510804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluoxetine ameliorates mucopolysaccharidosis type IIIA.
    Capuozzo A; Montefusco S; Cacace V; Sofia M; Esposito A; Napolitano G; Nusco E; Polishchuk E; Pizzo MT; De Risi M; De Leonibus E; Sorrentino NC; Medina DL
    Mol Ther; 2022 Apr; 30(4):1432-1450. PubMed ID: 35121108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain Targeting in MPS-IIIA.
    Sorrentino NC; Fraldi A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():630-8. PubMed ID: 27491210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice.
    McCarty DM; DiRosario J; Gulaid K; Muenzer J; Fu H
    Gene Ther; 2009 Nov; 16(11):1340-52. PubMed ID: 19587708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.